NanoViricides Inc. (NNVC)

[drkazmd65]

A Group Response to some of our (including my own) queries:

I - for the time being - am satisfied.


Re: Concerns Arising From 10-K Publication
Tuesday, September 30, 2014 9:21 AM


From: "[e-mail]" <[e-mail]>To:


Gentlemen and Ladies,

A number of people have written me expressing concern about the “possible 6-9 month delay in the FluCide program"

As I’ve said publicly, FluCide remains our near-term disease target

Now what about that statement about a possible delay?

Remember the context of the statement. Every single possibility has to be mentioned (look at the risk factors) in the 10K whether it’s going to happen or not

As I see it, the only way the FluCide program would be delayed would be if the following two conditions were present:

#1) EbolaCide2 works incredibly well

AND

#2) We receive a phenomenal amount of money from all of the agencies now committed to eradicating the disease in order to ramp up the production of the Ebola drug.

Forgetting the humanitarian aspect of the treatment of Ebola patients and an opportunity to stop the epidemic in its tracks, and remembering that the flu alone kills 250,000-500,000 people per year, a successful Ebola program would allow earlier human administration as well as give us world-wide recognition and “put us on the map” as a serious player in the anti-viral space as an emerging biopharmaceutical company.

Here are the reasons:

I have learned from my discussions with health officials in the UK that the average length of stay for a case of complicated influenza is 12 days at 2500£/day. That’s 30,000£. Now imagine if a drug came along that could get a person out of the hospital a lot sooner. Of course, getting people out of the hospital sooner means that there is the potential to save tens of thousands of lives both here and in Europe.

So the potential sales numbers for the hospital cases are staggering and the prices that can be charged represent a % of the savings to the healthcare system. Increasing production leads to significant economies of scale and a lower production cost while still justifying pricing by looking at the economic savings to the health care system by getting people out of the hospital sooner.

In a bad flu (non-pandemic) year, they may be as many as 1,000,000 patients hospitalized in the US and EU alone. As I said many times in various presentations, under the “specials” program in the EU, a non-approved drug can be sold for full retail if it has met basic safety and efficacy standards. The same in the US under the new “Breakthrough Drug Act”.

Something to think about especially since there’s no drug for complicated influenza in hospitalized patients. I would imagine that the US would also like to stockpile some flu drug for a possible pandemic.

That’s why FluCide is staying squarely in our sights!

PS Please share this with whoever might be interested so those who are concerned can understand the context of the statement


Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange